RT Journal Article
SR Electronic
T1 Lineage-specific protection and immune imprinting shape the age distributions of influenza B cases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.30.20204909
DO 10.1101/2020.09.30.20204909
A1 Marcos C. Vieira
A1 Celeste M. Donato
A1 Philip Arevalo
A1 Guus F. Rimmelzwaan
A1 Timothy Wood
A1 Liza Lopez
A1 Q. Sue Huang
A1 Vijaykrishna Dhanasekaran
A1 Katia Koelle
A1 Sarah Cobey
YR 2020
UL http://medrxiv.org/content/early/2020/10/02/2020.09.30.20204909.abstract
AB How a history of influenza virus infections contributes to protection is not fully understood, but such protection might explain the contrasting age distributions of cases of the two lineages of influenza B. Fitting a statistical model to those distributions using data from New Zealand, we found they could be explained by historical changes in lineage frequencies combined with cross-protection between strains of the same lineage. In addition to protection regardless of the order of infection, we found additional protection against B/Yamagata in people first infected with it, similar to the immune “imprinting” observed in influenza A. While the data were not informative about imprinting protection against B/Victoria, B/Yamagata imprinting could explain the fewer B/Yamagata than B/Victoria cases in cohorts born in the 1990s and the bimodal age distribution of B/Yamagata cases. Characterizing antibody specificity after exposure could illuminate the link between birth cohorts’ infection histories and susceptibility to influenza B.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under grant DP2 AI117921 and CEIRS Contract No. HHSN272201400005C awarded to S.C. M.V. was supported by a William Rainey Harper Dissertation Fellowship by the University of Chicago. K.K. was supported by MIDAS CIDID Center of Excellence (U54-GM111274), V.D. was supported by NIH CEIRS Contract No. HHSN272201400006C, C.D. was supported by an Early Carreer Fellowship (1113269) from the Australian National Health and Medical Research Council. This work was completed in part with resources provided by the University of Chicago Research Computing Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding sources.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable. Only aggregated case data previously collected by epidemiological surveillance were used in the analyses.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData in the final format used in the analyses are available at https://github.com/cobeylab/influenza_B_distributions